Jesup & Lamont initiates coverage on MIV Therapeutics, Inc. (Nasdaq: MIVT) with a Buy rating and $2 price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE